Home › Uveal Melanoma › Massachusetts › Boston
Uveal Melanoma clinical trials in Boston, MA
5 studies for Uveal Melanoma are looking for participants at sites in and around Boston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
RecruitingPhase 3
- Dana Farber Cancer Institute, Boston
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
RecruitingPhase 1/2
- Massachusetts General Hospital, Boston
Neoadjuvant Darovasertib in Primary Uveal Melanoma
RecruitingPhase 3
- Massachusetts General Hospital, Boston
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
RecruitingPhase 2/3
- Massachusetts General Hospital, Boston
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
Recruiting
- Massachusetts General Hospital, Boston
Uveal Melanoma trials in other cities
- Philadelphia, PA7 studies
- Los Angeles, CA6 studies
- Nashville, TN6 studies
- New York City, NY5 studies
- Columbus, OH5 studies
- Houston, TX5 studies
- Denver, CO5 studies
- Scottsdale, AZ5 studies
- Miami, FL4 studies
- Tampa, FL4 studies
- Mountain View, CA4 studies
- Pittsburgh, PA4 studies
Other studies in Boston
- Breast Cancer111 studies
- Non-Small Cell Lung Cancer90 studies
- Cancer (all types)86 studies
- Colorectal Cancer63 studies
- Metastatic Cancer63 studies
- Lung Cancer62 studies
- Ovarian Cancer61 studies
- Prostate Cancer59 studies
- Depression52 studies
- Endometrial Cancer50 studies
- Heart Failure44 studies
- Acute Myeloid Leukemia44 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.